Related by context. All words. (Click for frequent words.) 73 selective androgen receptor modulator 72 ostarine 68 elotuzumab 67 lomitapide 67 Capesaris 67 Archexin 67 bicifadine 66 INCB# [001] 66 PSN# [002] 66 nalbuphine ER 66 alvespimycin 66 Triolex 66 AEG# 66 custirsen 66 tanespimycin 66 phase IIb clinical 66 phase IIb 65 phase IIb trial 65 ataluren 65 PS# [001] 65 AEGR 65 Symadex 65 phase IIa clinical 65 Nasulin 65 OHR/AVR# 65 GLPG# 65 oral prodrug 65 oral ridaforolimus 65 Phase IIB 65 CORT # 65 ACAPODENE 65 R#/MEM # 65 octreotide implant 65 DR Cysteamine 65 HuMax EGFr 64 teduglutide 64 Phase 2a trial 64 ISIS # 64 PXD# 64 Azedra 64 ozarelix 64 QNEXA 64 cannabinor 64 PRT# 64 davunetide intranasal AL 64 Microplasmin 64 bardoxolone 64 forodesine 64 INT# [002] 64 Phase IIb trials 64 eniluracil 64 Phase Ib study 64 HGS ETR1 64 Synavive 64 Phase Ib 64 Mipomersen 64 SARMs 64 Phase IIa trial 64 Pimavanserin 64 diarrhea predominant irritable 64 Phase Ib clinical 64 opioid induced bowel dysfunction 64 metaglidasen 64 GALNS 64 Bicifadine 64 dexpramipexole 64 Acapodene 64 PREOS 64 Traficet EN 64 eltrombopag 64 EndoTAG TM -1 64 alagebrium 64 rNAPc2 64 TRV# [001] 64 fenretinide 64 ruxolitinib 64 Phase IIIb clinical 64 Phase IIa trials 64 CTAP# Capsules 63 riociguat 63 Phase 2b study 63 Zerenex 63 phase IIb study 63 pharmacodynamic effects 63 Cetrorelix 63 AAG geldanamycin analog 63 ALTU 63 PRX # 63 Factor VIIa 63 PEG PAL 63 CA4P 63 baminercept 63 atacicept 63 MYDICAR ® 63 PDE4 inhibitor 63 Phase IIb clinical 63 Phenoptin 63 otelixizumab 63 Androxal TM 63 HGS# 63 Desmoteplase 63 PEG Interferon lambda 63 cathepsin K inhibitor 63 alvimopan 63 refractory gout 63 lumiliximab 63 Zybrestat 63 visilizumab 63 CIMZIA TM 63 CR# vcMMAE 63 MYDICAR 63 sargramostim 63 Amrubicin 63 Ozarelix 63 ThGRF 63 TACI Ig 63 TBC# 62 Nuvion 62 valopicitabine 62 ONCONASE 62 davalintide 62 ocrelizumab 62 selective androgen receptor modulators 62 Sym# 62 methylnaltrexone 62 dacetuzumab 62 Prestara 62 EVIZON 62 AzaSite Plus 62 TG# [003] 62 ganetespib 62 phase IIa 62 glufosfamide 62 HuMax CD# 62 hyperphenylalaninemia HPA due 62 Dapagliflozin 62 Lixivaptan 62 diabetic neuropathic pain 62 Squalamine 62 teriflunomide 62 PROMACTA 62 ZOLINZA 62 SILENOR 62 Atrasentan 62 phase 2a 62 KRN# 62 6R BH4 62 budesonide foam 62 lixivaptan 62 Pivotal Phase 62 dyskinesia PD LID 62 TELINTRA 62 rHuPH# 62 sodium glucose cotransporter 62 Empatic 62 Elagolix 62 ruboxistaurin 62 LibiGel ® 62 Ocrelizumab 62 CBLC# 62 BAY #-# 62 Aflibercept 62 ularitide 62 tolevamer 62 TRIOLEX 62 CEQ# 62 deforolimus 62 Exherin TM 62 virus HCV protease inhibitor 62 Phase 1b trial 62 oral deforolimus 62 Phase 2b clinical trials 62 Corlux 62 atrasentan 62 INCB# [002] 62 pradefovir 62 Phase 2a clinical 62 Zemplar Capsules 62 BCX# 62 ONCONASE R 62 NOX E# 62 Phase 2b Clinical Trial 62 tolvaptan 62 Tasimelteon 62 Bezielle 62 Phase IIb clinical trials 62 Phase Ib clinical trials 62 Kamada AAT 62 lixisenatide 62 vidofludimus 62 Cannabinor 62 Blinatumomab 62 Veronate 62 Serdaxin 62 pomalidomide 62 Amigal 62 Aliskiren 62 TMC# [002] 61 cancer immunotherapies 61 nonclinical studies 61 Initiate Phase 61 FOLOTYN ® 61 Phase 2a 61 mixed dyslipidemia 61 TRO# 61 BZL# 61 HuLuc# 61 IV Busulfex 61 RSD# oral 61 iniparib 61 mapatumumab 61 TLK# 61 motesanib 61 odanacatib 61 LymphoStat B belimumab 61 IRX 2 61 YONDELIS 61 pramlintide 61 investigational monoclonal antibody 61 Phase #b/#a 61 albiglutide 61 registrational trial 61 Phase 1b 61 PEG SN# 61 bardoxolone methyl 61 dirucotide 61 ELND# 61 ACV1 61 clinical pharmacology studies 61 thymalfasin 61 SRT# [003] 61 Personalized Immunotherapy 61 MAXY VII 61 Spiegelmer ® 61 Fibrillex TM 61 trodusquemine 61 Tyrima 61 ACTEMRA 61 celgosivir 61 JAK inhibitor 61 calcitonin 61 Chrysalin 61 urocortin 2 61 glucokinase activator 61 Aurexis 61 relapsed multiple myeloma 61 Asentar 61 safinamide 61 ponatinib 61 Phase IIb 61 NLX P# 61 post menopausal osteoporosis 61 methylnaltrexone bromide 61 elagolix 61 ACTEMRA TM 61 IL# PE#QQR 61 Phase 2b clinical 61 edoxaban 61 torsemide ER 61 rFIXFc 61 confirmatory clinical 61 NV1FGF 61 LymphoStat B 61 rALLy clinical trial 61 Tavocept 61 Zoraxel 61 oral methylnaltrexone 61 Octreolin 61 zileuton 61 ulimorelin 61 midstage clinical 61 betrixaban 61 Urocidin 61 DXL# 61 Phase III Pivotal 61 parathyroid hormone PTH 61 PHX# 61 nucleotide analog 61 DPX Survivac 61 ELACYT 61 Phase 2b Trial 61 orBec 61 TH# [003] 61 Annamycin 61 daclizumab 61 velafermin belinostat 61 PSMA ADC 61 GAMMAGARD 61 Tezampanel 61 multicenter Phase 61 postoperative ileus POI 61 PREOS R 61 Ophena TM 61 RhuDex 61 OXi# 61 HGS ETR2 61 Plicera 61 Avanafil 61 cangrelor 61 DU #b 61 Dasatinib 61 DAVANAT 61 inhibitor RG# 61 liprotamase 61 corticosteroid dexamethasone 61 rhThrombin 61 INCB# [003] 61 mertansine 61 SNT MC# 61 eprotirome 61 pertuzumab 61 Cinquil 61 Ustekinumab 61 RAPAFLO 61 Phase 2b 61 lupus nephritis 60 QLT# 60 BRIM2 60 Meets Primary Endpoint 60 CORLUX 60 obatoclax 60 Gabapentin GR 60 RNAi therapeutic targeting PCSK9 60 pramlintide metreleptin 60 First Patient Dosed 60 Dacogen injection 60 GLYX 60 L BLP# 60 investigational humanized monoclonal antibody 60 AVE# 60 HCV protease inhibitors 60 Cethromycin 60 lintuzumab 60 Chemophase 60 Azedra TM 60 Parkinson disease levodopa induced 60 Lisofylline LSF 60 Leukine 60 Randomized Phase 60 confirmatory Phase III 60 HuMax CD4 60 Rigel R# 60 nab paclitaxel 60 Xcytrin R 60 tafamidis 60 Myocet 60 dose cohort 60 GFT# 60 SomatoKine 60 AQ4N 60 Cloretazine R VNP#M 60 SUCCEED trial 60 PD LID 60 Phase III Clinical Trial 60 CoFactor 60 Cleviprex TM clevidipine 60 teplizumab 60 HQK 60 JAK2 inhibitor 60 Darusentan 60 PEGylated interferon beta 1a 60 Prodarsan 60 darusentan 60 Phase III clinical 60 MAGE A3 ASCI 60 BRAF inhibitor 60 Vilazodone 60 metastatic castration resistant 60 Panzem 60 velafermin 60 delafloxacin 60 Ramoplanin 60 Phase Ib II 60 initiate Phase 1b 60 PROSTVAC VF 60 multicenter Phase II 60 Dextofisopam 60 PANVAC VF 60 talactoferrin 60 Nanobody 60 Phase 2a clinical trials 60 STRIDE PD 60 faropenem 60 NGX# 60 beta 1a 60 LY# [003] 60 GAMMAGARD LIQUID 60 LymphoStat B TM 60 TREDAPTIVE 60 EOquin 60 CB2 selective receptor agonist 60 Viprinex TM 60 OMP #R# 60 castrate resistant prostate cancer 60 Omigard 60 favorable pharmacokinetic profile 60 phase Ib 60 ApoB SNALP 60 Fx #A 60 THR beta agonist 60 #mg dose [002] 60 Vandetanib 60 PEGylated anti 60 Ketotransdel 60 apremilast 60 GSK# [002] 60 sapacitabine 60 investigational protease inhibitor 60 tgAAC# 60 volociximab 60 Troxatyl 60 arzoxifene 60 IIa trial 60 R#/MEM 60 Virulizin ® 60 Fibrin Pad 60 insulin sensitizers 60 SCH # 60 canakinumab 60 Phase IIa clinical 60 RLY# 60 reslizumab 60 sunitinib malate 60 RAPAFLO R 60 Fodosine 60 maribavir 60 enzastaurin 60 placebo controlled clinical 60 iSONEP 60 SAR# [002] 60 ATL# [001] 60 IMC A# 60 GRNCM1 60 Phase IIa 60 tesofensine 60 ALN TTR 60 Golimumab 60 tremelimumab 60 OMP #M# 60 huC# DM4 60 teriparatide 60 IND submission 60 initiate Phase 2b 60 PRX# 60 EVIZON TM 60 Sutent sunitinib 60 oral FTY# 60 IAP inhibitor 60 CDP# 60 ATACAND 60 tramiprosate Alzhemed TM 60 CG# [003] 60 ProSavin 60 vandetanib 60 metastatic sarcomas 60 Clolar ® 60 Xanafide 60 torezolid phosphate 60 Safinamide 60 DPP4 inhibitor 60 TKM ApoB 60 Telintra 60 Iloperidone 59 Glufosfamide 59 Technosphere Insulin 59 Muraglitazar 59 Naproxcinod 59 dimebon 59 rolofylline 59 Androxal ® 59 ENMD # 59 lintuzumab SGN 59 Phase IIb trial 59 MEND CABG II 59 zanolimumab 59 CRMD# 59 Genz # 59 CCR9 antagonist 59 Octreotide 59 Insegia 59 XL# XL# XL# XL# 59 linaclotide 59 PDE# inhibitors 59 ORMD 59 orally administered inhibitor 59 BENICAR HCT 59 PNP inhibitor 59 IAP inhibitors 59 humanized anti 59 plasma kallikrein inhibitor 59 Prodarsan ® 59 placebo controlled Phase 59 Novolimus 59 tasimelteon 59 sodium thiosulfate STS 59 Zenvia ™ 59 CCR5 antagonist 59 ATL/TV# 59 GLP1 agonist 59 Zolinza 59 omecamtiv mecarbil 59 bifeprunox 59 pharmacodynamic profile 59 dextromethorphan quinidine 59 Altastaph 59 antibody MAb 59 Bortezomib 59 virologic response 59 rindopepimut 59 olaparib 59 APPRAISE 59 NP2 Enkephalin 59 tiapamil 59 brivaracetam 59 DPP4 59 CYT# potent vascular disrupting 59 oral rivaroxaban 59 metabolic parameters 59 PROVENGE sipuleucel T 59 CRD5 59 AZILECT R 59 KNS # 59 preclinically 59 R roscovitine 59 CCX# B 59 darapladib 59 Anacetrapib 59 Phase #b/#a clinical 59 bosentan 59 davunetide 59 DCCR 59 MEK inhibitor 59 ARIKACE ™ 59 Metastatic Melanoma 59 hour bronchodilation 59 Civacir 59 DDP# 59 Stedivaze 59 evaluating tivozanib 59 BAL# [002] 59 JAK inhibitors 59 preclinical efficacy 59 Liprostin 59 Excellarate TM 59 bafetinib 59 Elocalcitol 59 Romidepsin 59 mipomersen 59 Proxinium TM 59 CIMZIA TM certolizumab pegol 59 IDX# 59 Phase 1a clinical 59 MAXY alpha 59 Carfilzomib 59 RNAi therapeutic targeting 59 Imprime PGG 59 CD# CEA 59 CaPre TM 59 zileuton CR 59 Study GL# 59 preclinical toxicology 59 Guanilib 59 CD# antibody [001] 59 multiple ascending dose 59 compound INCB# 59 oxypurinol 59 C1 INH 59 Icatibant 59 SGLT2 inhibitor 59 II Clinical Trial 59 NDA resubmission 59 trial evaluating PRX# 59 Diabetic Macular Edema DME 59 pharmacokinetic PK study 59 Unit Dose Budesonide 59 urate lowering 59 TELCYTA 59 milatuzumab 59 tezampanel 59 Phase 2a Clinical Trial 59 initiate Phase IIb 59 pseudobulbar affect PBA 59 LAF# 59 IMA# 59 avanafil 59 Epanova 59 factor VIIa 59 desvenlafaxine succinate 59 ILUVIEN ® 59 Initiated Phase 59 ICA # 59 CCX# 59 Apoptone 59 adalimumab Humira 59 MGCD# [001] 59 regorafenib 59 multicenter Phase III 59 Lpathomab 59 RGB # 59 DermaVir Patch 59 posaconazole 59 cilengitide 59 OncoVEX GM CSF 59 mGluR2 NAM 59 PRTX 59 ospemifene 59 varespladib 59 GTx 59 Saforis 59 Locteron ® 59 Interferon alpha 59 MAXY G# 59 sitaxsentan 59 dose escalation phase 59 pegylated interferons 59 Firazyr 59 Posiphen 59 Surfaxin LS 59 μg dose 59 AOD# [002] 59 Vicriviroc 59 Zarnestra 59 OvaRex ® MAb 59 anticancer activity 59 ELADUR 59 generation antisense inhibitor 59 rFVIIIFc 59 Cloretazine 59 cystinosis patients 59 Egrifta 59 Allovectin 7 R 59 oxymorphone ER 59 Locteron 59 Resten NG 58 Viramidine 58 ALGRX 58 cariprazine 58 Onconase 58 EDARBI 58 EGS# 58 Romiplostim 58 Trofex 58 VEGF Trap 58 Oral NKTR 58 GRN# 58 novel VDA molecule 58 acyclovir Lauriad R 58 dapagliflozin 58 ISTODAX 58 incyclinide 58 PEG INTRON 58 BLA submission 58 liposomal formulation 58 subcutaneous PRO 58 generation purine nucleoside 58 leading oral taxane 58 tramiprosate 58 neurogenic orthostatic hypotension 58 systemically administered 58 MOZOBIL 58 Abiraterone acetate 58 oral salmon calcitonin 58 ibandronate 58 Marqibo 58 RhuDex TM 58 serum uric acid sUA 58 NXL# 58 comparator arm 58 antitumor efficacy 58 MGd 58 Nanobody ® 58 edifoligide 58 prucalopride 58 EOquin TM 58 VA# [002] 58 ATL# [002] 58 MEK inhibitor RDEA# 58 Virulizin R 58 subcutaneous formulation 58 Vidaza azacitidine 58 PROSTVAC TM 58 blinatumomab 58 vascular disrupting agent 58 intranasal formulation 58 ocular formulation 58 Aurora kinase inhibitors 58 prGCD 58 primary hypercholesterolemia 58 laquinimod 58 CRx 58 MDV# 58 ORENCIA R 58 Pradefovir 58 PRADAXA 58 Proquin XR 58 AMD# [003] 58 Phase Ia 58 decitabine 58 belinostat 58 targeted radiotherapeutic 58 ALN PCS 58 Degarelix 58 GTC recombinant human 58 BENLYSTA ™ 58 maximally tolerated dose 58 bosutinib 58 antitumor effects 58 APTIVUS 58 Anturol TM 58 LY# [002] 58 Torisel 58 STELARA TM 58 cell lymphoma CTCL 58 squalamine 58 trastuzumab Herceptin R 58 Neurodex 58 dexanabinol 58 APD# 58 Kepivance 58 Cloretazine ® 58 vicriviroc 58 Actemra tocilizumab 58 docetaxel Taxotere R 58 Itopride 58 Testosterone MDTS ® 58 CIMZIA ™ 58 Phase #/#a trial 58 FASLODEX 58 ixabepilone 58 orally bioavailable 58 Diamyd ® 58 efficacy endpoint 58 RANK Ligand inhibitor 58 CINQUIL 58 ALKS 58 painful diabetic neuropathy 58 Laquinimod 58 JAK3 inhibitor 58 sorafenib tablets 58 STX# 58 relapsed MM 58 MoxDuo ® IR 58 rhIGF-I/rhIGFBP-3 58 pharmacokinetic PK 58 Phase 1b clinical 58 microplasmin 58 APTIVUS r 58 angiogenesis inhibitor 58 Heplisav 58 PEGPH# 58 MKC# MT 58 selective modulator 58 active comparator 58 catheter occlusion 58 GSK# [001] 58 RDEA# 58 postoperative ileus 58 danoprevir 58 NATRECOR R 58 investigational therapies 58 Phase III 58 Theratope 58 metreleptin 58 UPLYSO 58 PLK1 SNALP 58 S/GSK# 58 apaziquone 58 AeroLEF TM 58 Silodosin 58 metformin sulfonylurea 58 Phase #/#a 58 Actilon 58 radezolid 58 diabetic gastroparesis 58 CCR5 mAb 58 Tesetaxel 58 Phase 1a 58 Neulasta ® 58 lucinactant 58 Fabry Disease 58 aldehyde dehydrogenase ALDH2 deficiency 58 ZYBRESTAT 58 midstage studies 58 bile duct tumor 58 lorvotuzumab mertansine 58 XL# SAR# 58 mesylate tablets 58 efficacy tolerability 58 Relivar 58 Cardio Vascu Grow 58 Reverset 58 dasatinib Sprycel 58 MyVax 58 Numax 58 Pruvel 58 taranabant 58 pharmacodynamic PD 58 Targretin 58 Tekamlo 58 Velcade bortezomib 58 RhuDex ® 58 AZD# 58 tipranavir 58 CYT# 58 morphometric vertebral fractures 58 Aptivus ® 58 octreotide 58 UVIDEM 58 fosbretabulin 58 Amplimexon 58 Tarceva TM 58 midstage clinical trials 58 DAPT 58 pharmacokinetic studies 58 Alocrest 58 MEK inhibitors 58 aclidinium bromide 58 EMPOWER ™ 58 entinostat 58 tocilizumab 58 Fenretinide 58 Lu AA# 58 ALISTA 58 docetaxel chemotherapy 58 ACOMPLIA R 58 TOCOSOL Paclitaxel 58 Angiocept 58 APF# 58 sorafenib Nexavar 58 nitazoxanide 58 eliglustat tartrate 58 Phase 2b trial 58 NNR Therapeutics 58 Saxagliptin 58 Dalbavancin 58 interferon gamma 1b 58 NPC 1C 58 thetreatment 58 occlusion PAO 58 canagliflozin 58 Melphalan 58 Exelixis compounds 58 tesmilifene 58 CINTREDEKIN BESUDOTOX 58 eosinophilic asthma 58 MACUGEN 58 viral kinetics 58 Androxal 58 mGluR5 negative 58 candesartan cilexetil 58 Omacetaxine 58 hypoxia activated prodrug 58 pan HDAC inhibitor 58 registrational 58 alemtuzumab Campath 58 abiraterone acetate 58 vivo validation 58 neratinib 58 PPAR gamma agonist 58 TASKi3 58 vernakalant oral 58 Panzem R 58 #I TM# 58 dose limiting toxicities 58 Spheramine 58 MEND CABG 58 secondary efficacy endpoints 58 mGluR5 NAM 57 cMET 57 PSN# [001] 57 busulfan 57 REG1 57 Pancreate 57 Rezular 57 Entereg R 57 Fortical R 57 CRLX# 57 receptor tyrosine kinase inhibitor 57 Pirfenidone 57 MORAb 57 azilsartan medoxomil 57 LHRH antagonists 57 tranilast 57 Mepact 57 Behcet uveitis 57 ascending dose 57 insulin sensitizing 57 EDEMA3 trial 57 midstage trials 57 Boceprevir 57 DFMO 57 Aplidin 57 Parathyroid Hormone 57 BRIM3 57 Panzem R NCD 57 SinuNase 57 Phase IIIb 57 NUVIGIL 57 Cimzia TM 57 Bisphosphonate 57 HspE7 57 antiviral efficacy 57 NATRECOR ® 57 terlipressin 57 Rebif ® 57 zonisamide SR 57 ZD# [001] 57 Ambrisentan 57 Phase 2a Trial 57 GW# [003] 57 Ataluren 57 metastatic hormone refractory 57 Optiquel ™ 57 hepatic encephalopathy 57 MAA submission 57 Syncria 57 Initiates Phase II 57 PF # [002] 57 fostamatinib 57 pharmacokinetics PK 57 lasofoxifene 57 Canvaxin 57 GEM OS2 57 Protexia R 57 Horizant 57 dextofisopam 57 Xinlay 57 Phase Ib Clinical Trial 57 Sulonex TM 57 trastuzumab DM1 57 erlotinib Tarceva ® 57 dose escalation Phase 57 multiple myeloma MM 57 oral bioavailability 57 Epratuzumab 57 Pivotal Phase III 57 ADX# 57 SAR# [004] 57 difluprednate 57 Irinotecan 57 vosaroxin 57 AZX# Phase 57 NEBIDO 57 tipifarnib 57 Telbivudine 57 D aspartate NMDA receptor 57 direct thrombin inhibitors 57 sitagliptin 57 ZFP Therapeutic 57 Lubiprostone 57 LCP Tacro 57 BLA filing 57 XL# XL# 57 antiangiogenic 57 ADVANCE PD 57 ritonavir boosted danoprevir 57 pharmacological chaperone 57 temsirolimus 57 FOLPI 57 vorinostat 57 CDK inhibitor 57 INS# [001] 57 tezampanel NGX# 57 APOPTONE 57 elvitegravir 57 Forteo teriparatide 57 Enzastaurin 57 rasagiline tablets 57 candidate Zenvia 57 VitiGam 57 cediranib 57 ATHX 57 ritonavir boosted 57 proteasome inhibitor 57 CTA# Injection 57 Phase III trials 57 Vidofludimus 57 serum phosphate 57 RAV# 57 SYMMETRY trial 57 AZILECT ® 57 XmAb# 57 plus prednisone 57 ASONEP 57 IMC #B 57 BrachySil TM 57 amrubicin 57 Febuxostat 57 Promacta 57 dose escalation trial 57 r hGH 57 ADAGIO study 57 nucleoside analog 57 casopitant 57 enoximone 57 rhFVIIa 57 CD3 monoclonal antibody 57 inhaled formulation 57 pioglitazone HCl